When was Immunis.AI founded?

Immunis.AI was founded in 2012 and raised its 1st funding round 7 years after it was founded.

Where is Immunis.AI located?

Immunis.AI is headquartered in Royal Oak, United States.

How many employees does Immunis.AI have?

As of Aug 31, 2026, the latest employee count at Immunis.AI is 4.

Is Immunis.AI a funded company?

Immunis.AI is a funded company, having raised a total of $40M across 2 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Sep 11, 2019.

When was the latest funding round of Immunis.AI?

Immunis.AI's latest funding was a $***** Series C round on Sep 29, 2021, with participation from 1 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.39B in funding in 2026 to date.

Where does Immunis.AI rank among its competitors?

Immunis.AI ranks 15th amongst 101 active competitors, of which 29 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Mirvie, which secured $23.7M in Jul, 2025.

Who are the top competitors of Immunis.AI?

Immunis.AI's top competitors include Artera, OncoCyte and MDxHealth. Among them, Mirvie secured the most recent funding round in July, 2025.

Immunis.AI - 2026 Company Profile, Funding & Competitors

Immunis.AI is a series C company based in Royal Oak (United States), founded in 2012. It operates as a Provider of platform for the detection of cancer. Immunis.AI has raised $40M in funding from Savitr Capital. The company has 101 active competitors, including 29 funded and 13 that have exited. Its top competitors include companies like Artera, OncoCyte and MDxHealth.

Company Details

Immunis provides a patented platform for the detection of cancer. The intelligentia platform combines machine learning for the development of disease-specific algorithms. The immune system rapidly reacts to threats, triggering an internal amplification structure that causes changes to RNA expression levels within immune cells. It provides real-time surveillance of gene expression of monocytes and lymphocytes obtained from a patient enables the detection of immune-response signal changes.

Website: immunis.ai
Social
Email ID: *****@immunis.ai, *****@immunis.ai
Phone Number: +1 **********

Key Metrics

Founded Year

2012

Location

Royal Oak, United States

Stage

Series C

Total Funding

$40M in 2 rounds

Latest Funding Round

Series C, Sep 29, 2021, $*****

Investors

Savitr Capital

Ranked

15^th among 101 active competitors

Employee Count

4 as on Aug 31, 2026

Similar Companies

Artera & 80 more

View Immunis.AI's full profile

Immunis.AI has raised a total funding of $40M over 2 rounds. Its first funding round was on Sep 11, 2019. Its latest funding round was a Series C round on Sep 29, 2021 for $*****. 1 investor participated in its latest round. Immunis.AI has 1 institutional investor.

Here is the list of recent funding rounds of Immunis.AI:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 29, 2021	7917998	Series C	2261362	8707172	5025286	1702911
Sep 11, 2019	6134591	Series B	9838425	2693992	Savitr Capital	4918895

Access funding benchmarks and valuations. Sign up today!

View details of Immunis.AI's funding rounds and investors

Immunis.AI's employee count trend

Immunis.AI has 4 employees as of Aug 26. Here is Immunis.AI's employee count trend over the years:

Uncover Immunis.AI's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Immunis.AI include Artera, OncoCyte and MDxHealth. Here is the list of Top 10 competitors of Immunis.AI, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Artera 2021, Menlo Park (United States), Series A	AI-derived prognostic biomarker test for cancer detection	$135M	Walden Catalyst, EDBI & 23 others	68/100
2nd	OncoCyte 2009, Irvine (United States), Public	Developer of non-invasive diagnostic tests solutions for the treatment of cancer	$15.3M	Geode Capital, Connor, Clark & Lunn Financial Group ... & 5 others	62/100
3rd	MDxHealth 2003, Irvine (United States), Public	Provider of epigenetic tests for personalized cancer assessment and treatment	-	Kreos Capital, Eiffel Investment Group & 13 others	60/100
4th	Opko Health 1991, Miami (United States), Public	Provider of molecular diagnostic products	-	Gates, Oracle & 1 others	58/100
5th	Codiak BioSciences 2015, Cambridge (United States), Public	Developer of exosome-based drugs and diagnostics for cancer treatment	$168M	Arch Venture Partners, Flagship Pioneering ... & 10 others	57/100
6th	Mursla 2017, London (United Kingdom), Seed	Provider of diagnostic device for cancer detection	$547K	Future Fund, TA Ventures & 26 others	55/100
7th	ProteoMediX 2010, Schlieren (Switzerland), Acquired	Developer of next-generation blood test for prostate cancer	$17.6M	Altos Ventures Management, Venture Kick & 3 others	55/100
8th	Miroculus 2014, San Francisco (United States), Acquired	Developer of MicroRNA profiling platform to detect genes in the sample	$48.4M	Cota Capital, Nazca & 11 others	50/100
9th	Mirvie 2019, San Francisco (United States), Series B	Provider of non-invasive diagnostic tests for pregnant women	$114M	Decheng Capital, Khosla Ventures & 10 others	49/100
10th	DotLab 2016, Branford (United States), Series A	Provider of a molecular diagnostic testing tool for endometriosis in women	$10M	CooperSurgical, Wilson Sonsini Goodrich & Rosati ... & 6 others	49/100
15th	Immunis.AI 2012, Royal Oak (United States), Series C	Provider of platform for the detection of cancer	$40M	Savitr Capital	45/100